Insider buying last 90 days
No open-market insider purchases were filed for VKTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every VKTX insider filing, plotted on the chart in Gekko.Open VKTX in Gekko
NASDAQ: VKTX
Viking Therapeutics (VKTX) Stock Analysis & Forecast
Oct 12 close
$28.34−0.17 (−0.6%)
Gekko Brief
AI summaryOct 12 closeThis week's news centers on Viking Therapeutics' obesity franchise, with the company initiating an exploratory oral maintenance dosing study for VK2735 in obese adults, alongside its fully enrolled VANQUISH-1 and VANQUISH-2 Phase 3 trials. Analyst commentary has been active, with Oppenheimer discussing a path to $120 and Canaccord Genuity maintaining a Buy rating with a $114 price target, implying 316% upside, against a consensus target of $95 cited in that report. Coverage also notes scrutiny of valuation following increased R&D spending and a new stock offering, alongside a price-to-book ratio of 8.1x mentioned in one summary.
VKTX closed at $28.34, down 0.6%, sitting below both its 50-day average of $32.73 and 200-day average of $32.96, with the 50-day below the 200-day. The stock has fallen 11.4% over one month, 25.4% over three months, and sits 19% lower over the past year, within a 52-week range of $25.77 to $43.15. The GekkoIndex reads 62.9, placing it in the Accumulation zone, while price sits 39.8% below Gekko Fair Value of $47.04.
Earnings are scheduled for 28 October, 15 days out, falling inside a typical 20-day holding window, with past reactions averaging 5.1% and 2 beats across 8 quarters. Options activity shows 1 unusual signal over the past 30 days, with call premium of $2,627,536 against put premium of $107,648. Seasonality over 5 years shows an average 20-day return of 13.1% from this point, with gains in 4 of those years. Analyst sentiment remains heavily tilted toward Buy ratings, 16 of 17 firms, with a consensus target of $94.71.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Viking Therapeutics price vs fair value
Close $28.34200-day averageGekko Fair Value $47.04
Viking Therapeutics quick facts
- Market cap
- $3.31B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$4.67
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.65
- Volume
- 2.82M avg 9.21M
- 1-year return
- −19.0%
- Typical daily move
- ±8.5%
- Typical 20-day move
- ±12.7%
- 50-day average
- $32.73
- 200-day average
- $32.96
- Next earnings
- Oct 28 after close
- Shares outstanding
- 127.2M
Viking Therapeutics swing-trade checklist
Viking Therapeutics scores 4 supportive, 0 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $28.34 is below the 50-day ($32.73) and 200-day ($32.96) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
62.9, Accumulation
Reading 62.9 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
39.8% below
Price is 39.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 30 days: 1 unusual options signal.
See smart money - Earnings riskheadwind
Reports in 16 days
Reports on Oct 28, 2026, 16 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+13.1% on average
From this point in the calendar, the next 20 trading days averaged +13.1% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Viking Therapeutics stock chart and price history
Viking Therapeutics closed at $28.34 on Oct 12, 2026, −19.0% over the past year, inside a 52-week range of $25.77 to $43.15.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −11.4%
- 3 months
- −25.4%
- 6 months
- −19.1%
- 1 year
- −19.0%
The full VKTX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open VKTX in Gekko
Follow Viking Therapeutics through every session
Put VKTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track VKTX in GekkoFree for 7 days. No credit card required.
About Viking Therapeutics
Viking Therapeutics works on experimental drugs for diseases tied to metabolism and the endocrine system, and has not yet brought a product to market. Its furthest-along candidate, VK2809, is a pill designed to act selectively on a thyroid hormone receptor and is being tested in mid-stage trials for patients with biopsy-confirmed non-alcoholic steatohepatitis as well as non-alcoholic fatty liver disease.
Beyond that lead program, the company runs a broader pipeline of oral compounds. VK5211 is a non-steroidal agent aimed at the androgen receptor, under study for people recovering from hip fracture surgery performed on a non-elective basis. VK0612 targets type 2 diabetes and is approaching mid-stage testing, while VK0214 is a second thyroid receptor beta compound being developed for X-linked adrenoleukodystrophy. Each program remains in the clinical trial stage rather than commercial sale.
Viking Therapeutics was established in 2012 and is based in San Diego, California. Its shares trade on the NASDAQ under the ticker VKTX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- vikingtherapeutics.com
Viking Therapeutics GekkoIndex: the smart money zone
Viking Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.9, in the Accumulation zone, up 0.6 points over five sessions.
62.9Accumulation
Up 0.6 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 34 | +5.7% | −1.6% | ||
| Accumulation (current zone) | 264 | 0.0% | +0.1% | ||
| Neutral | 336 | +0.1% | +4.0% | ||
| Distribution | 44 | +8.5% | +32.9% | ||
| Selling | 4 | Too few readings yet | |||
Average VKTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the VKTX price, zone by zone.Track VKTX in Gekko
Is Viking Therapeutics stock overvalued? Gekko Fair Value
Viking Therapeutics trades 39.8% below Gekko Fair Value of $47.04, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Viking Therapeutics shares are worth, recalculated every trading day.
$47.04
Gekko Fair Value, Oct 10, 2026
39.8% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open VKTX in Gekko
Viking Therapeutics insider and Congress trading
No open-market insider purchases were filed for Viking Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in VKTX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for VKTX, plotted on the chart in Gekko.Open VKTX in Gekko
Buybacks
Viking Therapeutics has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2023
- $37K
- As a share of market cap
- 0.00%
From company filings.
Unusual options activity last 30 days
1signal, 96% of the flagged premium in calls.
Latest: Bullish flow on Sep 25, $2.74M in unusual premium.
Hedge funds and billionaires quarter ended Sep 30
0of the funds Gekko tracks hold VKTX.
0added0opened0trimmed2sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Viking Therapeutics earnings: next date and track record
Viking Therapeutics reports on Oct 28, 2026, after the close (16 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Oct 28, 2026
Expected after the close, 16 days away
- EPS estimate
- −$1.07
2 of 8reports beat the EPS estimate
±5.1%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 29, 2026 AI summary
- What they said
- Viking Therapeutics' Q2 2026 earnings call focused on clinical and pipeline progress within its obesity franchise, operational updates and financial results. Management reported that the VANQUISH Phase III program for VK2735 (GLP-1/GIP dual agonist) is fully enrolled and proceeding on track for both subcutaneous and an oral tablet development program, with the oral Phase III program expected to initiate in Q4 2026. The company is also running a novel maintenance dosing study exploring weekly, every-other-week and monthly regimens and expects topline results later this quarter. Viking initiated a Phase I single ascending dose (SAD) for its amylin (DACRA/3019) program and plans multiple-path development including potential combination with VK2735. Financials showed materially higher R&D and G&A spend driven by clinical activity; net loss widened to $128.1M for the quarter and cash use is heavy this year but management expects tapering and reaffirms cash runway into 2028. Management emphasized hiring in clinical, regulatory, quality and commercial functions and described operational readiness for upcoming trials.
- Guidance
- - Oral Phase III program initiation expected in Q4 2026. - Topline results from the maintenance dosing study expected later this quarter (Q3 2026). - Phase I MAD results for DACRA/3019 expected in 2027 timeframe (post-SAD). - Management reiterated prior guidance that cash on hand is expected to fund operations into 2028.
- Risks flagged
- - Elevated cash burn and increased R&D spend leading to large quarterly net losses (net loss $128.1M for Q2 2026). - Clinical and tolerability uncertainty: maintenance dosing tolerability, higher-dose tolerability, and uncertainty on cross-trial read-throughs. - Manufacturing and supply considerations for oral tablet and expansion of CordenPharma relationship. - Competitive and real-world factors (use of off-trial GLP-1s/compounded products and competitive landscape). - Typical clinical development risks (timeline slippage, safety signals in later studies).
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 29, 2026 | −$1.10 est −$1.21 | — | −2.2% |
| Apr 29, 2026 | −$1.37 est −$0.92 | — | −3.7% |
| Feb 11, 2026 | −$1.38 est −$0.90 | — est $1.92M | +6.1% |
| Oct 22, 2025 | −$0.81 est −$0.70 | — | +2.9% |
| Jul 23, 2025 | −$0.58 est −$0.44 | — | +4.4% |
| Apr 23, 2025 | −$0.41 est −$0.34 | — | +0.7% |
| Feb 5, 2025 | −$0.32 est −$0.27 | — | −2.8% |
| Oct 23, 2024 | −$0.22 est −$0.25 | — | +18.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Viking Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Viking Therapeutics is $94.71, +234.2% from the last close, from 17 firms rating the stock in the last 90 days.
$94.71consensus 12-month target, +234.2% from the last close
Now $28.34Avg $94.71
Low $38High $125
Each firm’s latest rating in the last 90 days: 17 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 7 | Canaccord Genuity | $114 | +302.3% |
| Oct 7 | Truist Financial | $85 | +199.9% |
| Oct 6 | H.C. Wainwright | $102 | +259.9% |
| Oct 6 | Morgan Stanley | $95 | +235.2% |
| Oct 6 | Maxim Group | $70 | +147.0% |
+0.1%average 20-day move after past Accumulation readings
+13.1%average move over the next 20 trading days in the last 5 years
±8.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Viking Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Viking Therapeutics averaged +13.1% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +6.0% | 2 of 5 |
| Next 10 trading days | +6.1% | 2 of 5 |
| Next 15 trading days | +12.4% | 4 of 5 |
| Next 20 trading days | +13.1% | 4 of 5 |
| Next 30 trading days | +3.6% | 2 of 5 |
For scale, VKTX’s typical 20-trading-day move in either direction is about 12.7%.
Viking Therapeutics market cap and key statistics
Viking Therapeutics’s market cap is $3.31B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $3.31B
- EPS, TTM
- −$4.67
- Gekko Fair Value
- $47.04
Trading
- Volume
- 2.82M
- Avg volume, 20 days
- 9.21M
- 52-week high
- $43.15
- 52-week low
- $25.77
- Shares outstanding
- 127.2M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -88.8%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.65
- Typical daily move
- ±8.5%
- Typical 20-day move
- ±12.7%
Viking Therapeutics stock news this week
Coverage of Viking Therapeutics this week reads positive: 12 positive, 4 neutral and 2 negative headlines.
- Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.The Motley Fool, Oct 12
- Can Viking Therapeutics (VKTX) Justify Its Valuation On The VK2735 Oral Study Launch?Simply Wall Street, Oct 11
- Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?Fool - Investing News, Oct 10
- VK2735 Maintenance Study Could Be A Big Test For Viking Therapeutics StockSimply Wall Street, Oct 10
- Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to ConsiderYahoo! Finance Canada, Oct 9
- Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should KnowYahoo! Finance Canada, Oct 8
Viking Therapeutics peers
Viking Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Viking Therapeutics stock FAQ
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is $3.31B at the Oct 12, 2026 close of $28.34, with 127.2M shares outstanding.
What is the Viking Therapeutics stock forecast?
The consensus analyst 12-month price target for Viking Therapeutics is $94.71, +234.2% from the last close. Of the 17 firms that rated the stock in the last 90 days, 16 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Viking Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Viking Therapeutics is undervalued: the Oct 12, 2026 close of $28.34 is 39.8% below Gekko Fair Value of $47.04. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Viking Therapeutics report earnings next?
Viking Therapeutics is expected to report on Oct 28, 2026, after the market closes (16 days away). Analysts expect earnings of −$1.07 per share. Viking Therapeutics beat the earnings estimate in 2 of its last 8 reports, moving 5.1% on average across the report.
What is Viking Therapeutics’s 52-week high and low?
Viking Therapeutics’s 52-week high is $43.15 and its 52-week low is $25.77; it closed at $28.34 on Oct 12, 2026, −19.0% over the past year. Over the last five years the shares peaked at $99.41 on Feb 28, 2024.
Is Viking Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Viking Therapeutics?
Gekko flagged 1 unusual options signal in Viking Therapeutics over the last 30 days, with $2.63M of flagged premium in calls and $108K in puts. The latest, bullish flow, was on Sep 25, 2026 with $2.74M in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Viking Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.